PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$13.77
-0.09 (-0.65%)
▼
5d:
-3.77%
30d:
+12.13%
90d:
-19.43%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
15d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PHAR this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: PHAR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $13.77, which is considered slightly high relative to its 30-day fair value range of $12.62 to $13.89. The stock's valuation (Forward PE: 210.2) is in line with its historical norms (217.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $13.00, while resistance sits at $14.79.
Market Sentiment: PHAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+149.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $13.00, while resistance sits at $14.79.
Market Sentiment: PHAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+149.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$12.62 -
$13.89
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.5% below Wall St target ($34.35)
Trading Range Analysis
30-Day Trading Range
$12.62 -
$13.89
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$13.00
Resistance Level
$14.79
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
210.23
Wall Street Target
$34.35
(+149.5%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
210.2 vs 217.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$13.60
(-1%)
2-Year Target
$13.44
(-2%)
3-Year Target
$13.28
(-4%)
3-Yr Target (if PE normalizes)
(PE: 210→218)
$13.75
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 210.2, Growth: -71.6%)
$10.04
(+-27%)
Base:
(SPY PE: 21.8, Growth: -71.6%)
$1.04
(-92%)
Bear:
(PE: 18.5, Growth: -71.6%)
$0.88
(-94%)
📈
Valuation based on Current Earnings
Forward PE: 24.21 | Forward EPS (Implied): $0.57
Bull Case
$16.63
(+21%)
Analyst growth 15.0%, PE expands to 25.4
Base Case
$13.77
(0%)
Market implied 0.0%, PE stable at 24.2
Bear Case
$10.53
(-24%)
Severe decline -15.0%, PE contracts to 21.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 210.2 to 217.7
Stabilization Target:
$14.26
(+3.6%)
PE Expansion Potential:
+3.6%
Share & Embed Analysis
Last updated: July 14, 2026 3:07 AM ET
Data refreshes hourly during market hours. Next update: 4:07 AM
Data refreshes hourly during market hours. Next update: 4:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
